ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $3.67 billion. The enterprise value is $3.69 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 238.63 million shares outstanding. The number of shares has increased by 3.49% in one year.
| Current Share Class | 238.63M |
| Shares Outstanding | 238.63M |
| Shares Change (YoY) | +3.49% |
| Shares Change (QoQ) | -1.59% |
| Owned by Insiders (%) | 1.97% |
| Owned by Institutions (%) | 89.56% |
| Float | 233.83M |
Valuation Ratios
The trailing PE ratio is 17.96 and the forward PE ratio is 18.08.
| PE Ratio | 17.96 |
| Forward PE | 18.08 |
| PS Ratio | 7.48 |
| Forward PS | 6.32 |
| PB Ratio | 8.50 |
| P/TBV Ratio | 8.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 17.62 |
| EV / Sales | 7.55 |
| EV / EBITDA | 21.07 |
| EV / EBIT | 22.09 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.13, with a Debt / Equity ratio of 0.19.
| Current Ratio | 7.13 |
| Quick Ratio | 3.52 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.47 |
| Debt / FCF | n/a |
| Interest Coverage | 19.97 |
Financial Efficiency
Return on equity (ROE) is 63.17% and return on invested capital (ROIC) is 24.34%.
| Return on Equity (ROE) | 63.17% |
| Return on Assets (ROA) | 21.76% |
| Return on Invested Capital (ROIC) | 24.34% |
| Return on Capital Employed (ROCE) | 32.61% |
| Revenue Per Employee | $713,225 |
| Profits Per Employee | $305,762 |
| Employee Count | 685 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 1.20 |
Taxes
| Income Tax | -53.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.57% in the last 52 weeks. The beta is 0.45, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -19.57% |
| 50-Day Moving Average | 15.49 |
| 200-Day Moving Average | 17.89 |
| Relative Strength Index (RSI) | 51.97 |
| Average Volume (20 Days) | 3,461,647 |
Short Selling Information
The latest short interest is 17.56 million, so 7.36% of the outstanding shares have been sold short.
| Short Interest | 17.56M |
| Short Previous Month | 17.41M |
| Short % of Shares Out | 7.36% |
| Short % of Float | 7.51% |
| Short Ratio (days to cover) | 4.97 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $488.56 million and earned $209.45 million in profits. Earnings per share was $0.86.
| Revenue | 488.56M |
| Gross Profit | 267.28M |
| Operating Income | 167.02M |
| Pretax Income | 155.77M |
| Net Income | 209.45M |
| EBITDA | 175.13M |
| EBIT | 167.02M |
| Earnings Per Share (EPS) | $0.86 |
Full Income StatementBalance Sheet
The company has $61.39 million in cash and $83.12 million in debt, giving a net cash position of -$21.74 million or -$0.09 per share.
| Cash & Cash Equivalents | 61.39M |
| Total Debt | 83.12M |
| Net Cash | -21.74M |
| Net Cash Per Share | -$0.09 |
| Equity (Book Value) | 431.19M |
| Book Value Per Share | 1.81 |
| Working Capital | 346.17M |
Full Balance SheetMargins
Gross margin is 54.71%, with operating and profit margins of 34.19% and 42.87%.
| Gross Margin | 54.71% |
| Operating Margin | 34.19% |
| Pretax Margin | 31.88% |
| Profit Margin | 42.87% |
| EBITDA Margin | 35.85% |
| EBIT Margin | 34.19% |
| FCF Margin | n/a |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.49% |
| Shareholder Yield | -3.49% |
| Earnings Yield | 5.71% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ADMA Biologics is $27.67, which is 80.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.67 |
| Price Target Difference | 80.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 21.19% |
| EPS Growth Forecast (5Y) | 19.87% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
